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Human hematopoiesis was evaluated using the techniques of controlled stem 
cell differentiation, two-dimensional gel electrophoresis-based proteomics, and 
functional genomics. We provide the first report that glia maturation factor 
gamma (GMFG) is a cytokine-responsive protein in erythropoietin-induced and 
granulocyte-colony stimulating factor-induced hematopoietic lineage development. 
Results from global functional genomics analysis indicate that GMFG possesses 
several other features: hematopoietic tissue-specific gene expression, a promoter 
concentrated with high-score hematopoiesis-specif ic transcription factors, and pos- 
sible molecular coevolution with a rudimentary blood/immune system. On the 
basis of our findings, we hypothesize that GMFG is a hematopoietic-specific pro- 
tein that may mediate the pluripotentiality and lineage commitment of human 
hematopoietic stem cells. 
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Introduction 
Although it is widely accepted that the hematopoi- 
etic stem cell (HSC) is capable of both se!f-renewal 
and differentiation into all of the peripheral blood cell 
types, the mechanisms that control these self-renewal 
and differentiation processes remain a mystery ( 1 , 2 ) .  
To address this issue, we developed a special cul- 
ture system in which HSCs cultured for 14 days wiih 
erythropoietin (EPO) were recultured for another 14 
days with granulocyte-colony stimulating factor (G- 
CSF) and vice versa (that is, G-CSF-stimulated HSCs 
were recultured with EPO). This unique culture sys- 
tem provides both practical and theoretical platforms 
for further study in this area. Using this culture 
system, we observed phenotypic lineage interconver- 
sion between erythroid and myeloid cells derived from 
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To focus on the molecular aspects of 
hematopoiesis, we used proteomics and bioinformat- 
ics to further investigate lineage development and 
interconversion. Upon analysis of protein profiles 
from two-dimensional gel electrophoresis (2-DE), we 
discovered a protein spot that was responsive to 
specific cytokine signals that determine the forma 
tion of specific blood cell lineages. Using liquid 
chromatography-tandem mass spectrometry (LC- 
MS/MS), the protein was identified as glia mat- 
uration factor gamma (GMFG). Later, the cDNA 
sequence of the GMFG gene was confirmed using 
the reverse transcriptase-polymerase chain reaction 
(RT-PCR). 
The GMFG gene, also called the glia maturation 
factor beta homolog (GMFB-h) gene, was first re- 
ported by two groups in 1998 ( 4 , 5 ) .  Mao et al ( 4 )  
discovered the GMFG gene when sequencing cDNAs 
from CD34+ hematopoietic stem/progenitor cells. 
Asai et a1 ( 5 )  found the gene inadvertently when con- 
ducting a Northern blot experiment on GMFB in as- 
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trocytes. The full-length cDNA of GMFG is approx- 
imately 0.9 kb and encodes a protein of 142 amino 
acids. Results of an enzyme-linked immunoassay in- 
dicate that the GMFG gene is highly expressed in 
spleen, thymus, colon, and lung ( 6 ) .  GMFG has also 
been found in human serum at various ages; it was 
highly expressed in 21- to 30-year-old individuals and 
began to decrease rapidly in individuals older than 30 
years (6). In a previous study, the promoter analysis 
identified certain binding sites for transcription fac- 
tors (TFs) that were reported to be closely related to 
hematopoiesis ( 7). 
Although the function of GMFG remains unclear, 
another member of the same protein family, GMFB, 
has been well studied. GMFB is also a protein of 
142 amino acids and was initially identified as a 
growth/differentiation factor from vertebrate brains 
(8-12). This protein has several serine/threonine 
(Ser/Thr) phosphorylation sites and can be phospho- 
rylated with protein kinase A (PKA), protein kinase C 
(PKC), casein kinase I1 (CKII), and p90 ribosomal S6 
kinase (RSK) (13). The PKA-phosphorylated GMFB 
is a potent inhibitor of extracellular signal-regulated 
kinases 1 and 2 (ERKl/ERK2) and is a strong en- 
hancer of p38 (14,15). Both ERKl/ERK2 and p38 
belong to the same mitogen-activated protein kinase 
(MAPK) family. Thus, GMFB was considered to be 
a putative intracellular kinase regulator (16) and a 
modulator of intracellular signal transduction via its 
phosphorylation ( 6 ) .  In addition, a previous report 
suggested that GMFB may have played an important 
role in maintaining stem cell systems as they devel- 
oped during early metazoan evolution ( I  7). 
Here we provide a comprehensive bioinformatic 
analysis of GMFG, including promoter analysis, tis- 
sue/cell distribution analysis, and molecular evolu- 
tionary/phylum analysis using available DNA mi- 
croarray data banks. Our results support the hy- 
pothesis that GMFG may play an important role as a 
maintenance factor for HSC and as a regulation factor 
for hematopoietic lineage commitment. 
Results 
A cytokine-responsive protein in EPO- 
and G-CSF-induced HSC differentiation 
As shown in a previous report of our unique cul- 
ture system (3), we cultured AC133+ human HSCs 
with EPO for 14 d, which resulted in a definite 
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erythroid-lineage cell population that we termed El4 
cells (Figure 1A). Simultaneously, we cultured addi- 
tional AC133+ cells with G-CSF for 14 d, which re- 
sulted in a definite myeloid-lineage cell population 
that we termed G14 cells (Figure 1C). When the El4 
and G14 samples were analyzed by 2-DE, we found 
an interesting protein spot that exhibited an approx- 
imately 10-fold difference in density between the ery- 
throid and myeloid cell populations. This protein was 
present in untreated AC133+ cells, termed DO cells. 
Its expression decreased with EPO stimulation and 
increased slightly with G-CSF stimulation (Figure 1B 
and D, respectively). Furthermore, when we recul- 
tured the El4 cells with G-CSF for another 14 d, 
the erythroid cells switched to a myeloid cell popula- 
tion termed E14+G14, in which the protein spot in- 
creased (Figure 1E). Conversely, when we recultured 
the G14 cells with EPO for another 14 d, the myeloid 
cells switched to an erythroid cell population termed 
G14-+E14, in which the protein spot decreased (Fig- 
ure 1E). Therefore, the cytokine-responsive character 
of this protein can be seen not only in HSCs but also 
in El4 erythroid cells and G14 myeloid cells. The 
latter observation is important because it may set up 
a molecular basis for the lineage switch that we ob- 
served in earlier research ( 9 ) .  
Identification of GMFG as the 
cytokine-responsive protein 
Upon repeating 2-DE on G14 samples, we manually 
excised and collected the gel spots and analyzed the 
proteins by LC-MS/MS analysis (Tables 1 and 2). We 
used GMFB as a reference and thoroughly compared 
the peptide sequences identified by MS. The peptide 
difference between GMFG and GMFB permits us to 
finally identify our protein as GMFG (Figure 2A). 
At the level of transcription, an RT-PCR validation 
of the results was performed with both the erythroid 
and myeloid lineages (Figure 2B). 
Differential expression of GMFG only 
observed at the protein level 
After Zhang et al (18) reported the GMFG gene as 
one of the new genes expressed in CD34+ HSCs, they 
designed a gene chip experiment to investigate the 
transcription of 300 new genes in various hematopoi- 
etic cell lines, including NB4, HL60, U937, K562, and 
Jurkat. Their results revealed no differential expres- 
sion of the GMFG gene among these cell lines (18). 
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Fig. 1 A protein spot showing differential expression between erythroid and myeloid lineages. A and C .  Morphology 
of erythroid and myeloid cells, respectively. B and D. 2-DE of erythroid and myeloid cells, respectively. The protein 
spot of interest is indicated by the arrow in the enlargements of the 2-D gels. E. Normalized intensity value of the 
protein spot as it changed during lineage development and switching. The five cell populations, indicated by DO, E14, 
G14, E14&+G14, and G14jE14,  are defined in Materials and Methods. 
Fig. 2 The protein spot of interest was identified as GMFG. A. Protein sequence alignment for GMFG and GMFB. 
Amino acid differences are underlined within the fragments that were identified by MS in this study. GMFG was 
confirmed by this comparison. B. Comparisons of the GMFG mRNA level and its corresponding protein level during 
lineage differentiation. Three cell population samples were collected: DO for AC133+ hematopoietic stem/progenitor 
cells, E l4  for erythroid cells, and G14 for myeloid cells (see Materials and Methods). The mRNA was evaluated by 
RT-PCR and the protein was evaluated by 2-DE. For comparison, both the mRNA value and the protein value of DO 
were normalized to 1.0. All other values were displayed proportionally. 
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Table 1 The General Information from LC-MS/MS Data 
Protein identified Accession No. Total score Mass (Da) PI Database Percentage covered 
glia maturation factor gi 4758440 242 16,801.31 5.1 NCBI (Human) 26.06% 
gamma (GMFG) 
Table 2 Precursor Mass and Ion Score for Each of the Three Peptides Identified by LC-MS/MS 
Peptide Residue number Precursor mass Ion score 
FVVYSYKWHDDGR 68 - 81 1747.77 79.96 
LVQTAELTKVFEIR 111 - 122 1646.88 87.69 
MELPERQPR 59 - 67 1155.55 36.59 
In the studies herein, our RT-PCR results also demon- 
strated that the GMFG gene was not significantly 
differentially expressed between El4 erythroid and 
G14 myeloid cells (Figure 2B). However, at the level 
of protein expression, GMFG exhibited a greater than 
10-fold difference (Figure 1). The results of many re- 
searchers who have conducted simultaneous gene ex- 
pression and proteomic studies confirm the fact that 
only a small percentage of genes show a statistically 
significant correlation between the expression levels 
of their corresponding mRNAs and proteins (19). It 
is widely accepted that the primary cause of the dis- 
crepancy between gene and protein expression is the 
post-translational modification of proteins. In our re- 
search, we noticed that GMFG is a protein with six 
consensus phosphorylation sites ( I  6 ) .  An experiment 
is planned to evaluate the potential contributions of 
post-translational modifications of GMFG to our 2- 
DE results and to cell lineage formation. The results 
presented herein provide another example support- 
ing the inevitable trend of researchers to approach a 
biomedical problem with the combined, comprehen- 
sive techniques of genomics, proteomics, and bioin- 
formatics. 
Recently, gene profile-based studies of the molecu- 
lar signature of stem cells (2 ,2U)  have revealed valu- 
able information; however, results from our experi- 
ments suggest that the’ “total picture” might not be 
obtained until the protein profile is completed. It may 
not be surprising to find considerable inconsistencies 
between the gene signature and the protein signature 
within the same stem cell. 
No significant GMFB transcription was observed 
for both lineages at 28 days’ scale (Figure 3). The 
536-bp cDNA product of the RT-PCR wits sequenced 
and confirmed to be GMFG (data not shown). The 
GMFG gene expression profiling is displayed in Fig- 
ure 4. The results of GMFG promoter analysis are 
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demonstrated in Figure 5,  and the GMFG’s molecu- 
lar evolutionary analysis is shown in Figure 6. 
Discussion 
Possible mechanism of GMFG respon- 
siveness to cytokines 
The mechanism of GMFG responsiveness to HSC cy- 
tokines and its involvement in regulating HSC differ- 
entiation remains unknown. From previous research 
on GMFB, we know that the PKA-phosphorylated 
form of GMFB potently inhibits ERKl/ERK2 and 
strongly enhances p38 ( I 4 , 1 5 ) .  These findings led 
us to consider the possibility that phosphorylation/ 
dephosphorylation may be involved in the mechanism 
by which GMFG regulates HSC differentiation. Be- 
cause GMFG and GMFB have the same Ser/Thr 
phosphorylation molecular characteristics, it is as- 
sumed that the major cellular biochemical activities 
of these two proteins will be similar ( 2 1 ) .  It has been 
well documented that during hematopoiesis, Ser/Thr 
phosphorylation plays an important role in signal 
transduction in HSC differentiation and proliferation. 
For example, both the inhibition of MAP1/2 (22 )  
and the enhancement of p38 (23 )  can increase ery- 
thropoiesis. PKA-phosphorylated GMFB is known 
to be an inhibitor of MAP1/2 and an enhancer of p38 
(14,15), and there is evidence that PKA is involved 
in erythropoiesis (24 ). We have begun experiments 
to investigate the roles of GMFG in these processes. 
GMFG and hematopoietic development 
Tissue-specific distribution 
By using a global bioinformatics profiling strategy, we 
collected all accessible microarray data about GMFG 
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Fig. 3 Validation of GMFG by RT-PCR. A. RT-PCR results for GMFG and GMFB during erythroid differentiation 
induced by EPO. Samples were collected at 0, 7, 14, 21, and 28 d, respectively. B. RT-PCR results for GMFG and 
GMFB during myeloid differentiation induced by GCSF. Samples were collected at 0, 7, 14, 21, and 28 d, respectively. 
gene expression. The expression level distribution of 
the GMFG gene in human tissues and cell lines is 
shown in Figure 4. It can be seen that the GMFG 
gene is highly expressed in blood (including in myeloid 
leukemia and lymphoid leukemia cell lines), thymus, 
spleen, fetal liver, and lung. It is noteworthy that 
most of the tissues with high levels of GMFG expres- 
sion are related to the blood and immune systems. 
The distribution pattern is consistent with the re- 
sults of our recent Northern blot experiment (data 
not shown) and is also very similar to the findings 
of a recent study that used immunoassays to deter- 
mine the distribution of the GMFG protein (6). Our 
bioinformatics data also indicates that the expres- 
sion of the GMFG gene in nervous/brain tissue is not 
higher than that in any other tissue, which confirmed 
Walker’s finding (25) ,  and thus the expression distri- 
bution pattern of the GMFG gene differs from that 
of the GMFB gene. It is interesting to note that 
the Burkitt’s lymphoma cell line Daudi differs greatly 
from the Burkitt’s lymphoma cell line Raji with re- 
spect to GMFG gene expression (Figure 4), with the 
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latter cell line having a much lower level of expression 
of the GMFG gene. 
High-score hernatopoietic TF binding sites of 
the GMFG promoter 
The continual replacement of blood cells is essential 
for vertebrates. This process is largely dependent on 
hematopoietic, lineage-specific TFs (26). We evalu- 
ated the 750-bp GMFG promoter region for TF bind- 
ing sites using our new scoring system. By setting 
a threshold score of 0.900, we found 20 putative TF 
binding sites with scores ranging from 0.900 to 1.000 
(Figure 5). Among these high-score sites, there are 
three GATA-1 binding sites, with scores of 0.902, 
0.906, and 0.963, respectively; one GATA-2 binding 
site, with a score of 0.921; two GATA-3 binding sites, 
with scores of 0.909 and 0.922, respectively; two AML- 
l a  (27) binding sites, each with a perfect score of 
1.000; three MZFl (28) binding sites, with scores of 
0.904, 0.930, and 0.957, respectively; one Lyf-1 bind- 
ing site, with a score of 1.000; and one c-Ets-1 binding 
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Fig. 4 Global GMFG gene expression profile. 
site, with a score of 0.922. All of these TFs are related 
to erythroid, myeloid, T cell, and B cell differentiation 
and proliferation. In particular, AML-la is considered 
to be a critical (master) regulator of hematopoietic 
cell development (27). Many hematopoiesis-specific 
genes are activated by AML-la, including interleukin- 
3, granulocyte-macrophage-colony stimulating factor 
(GM-CSF), CSF-lR, and the T cell receptor (27). 
AML-la may also be involved in HSC maintenance 
and renewal (26). Its tissue-specific expression oc- 
curs mostly in thymus and spleen (29) ,  which is con- 
sistent with the tissue specificity expression of the 
GMFG gene, indicating that the latter might be a 
downstream regulator for AML-la. 
GMFG protein coevolved with increasing com- 
plexity of the blood/immune system 
In addition to  the GMFGs from human, mouse, and 
rat that were reported by others (16),  we have de- 
tected the protein sequences of GMFG in chimpanzee, 
monkey, pig, and cow using our GeneKey software. 
We also detected GMFs in frog, zebrafish, the spotted 
green pufferfish Tetraodon nigroviridis, the filarial 
worm Brugia malayi, mosquito, and the nematode 
Caenorhabditis briggsae. GMF in the sponge was re- 
ported by Muller et al (17). Selected multiple se- 
quence alignments are shown in Figure 6A. From an 
evolutionary perspective, we can see that GMF genes 
that exist in Metazoa probably originated via dupli- 
cation of the actin-depolymerizing factor (ADF) gene 
(data not shown). Late in the evolution of the Ver- 
tebrata, we find the two family members GMFG and 
GMFB. Using our Sandwich Sequence Alignment soft- 
ware, we also found a GMF in the carp (Cyprinvs 
carpio) (30) that is very similar to human GMFB 
and GMFG, with slightly more similarity to GMFG 
(Figure 6B). This observation might imply that ani- 
mals of the early stages of vertebrate evolution may 
have a single GMF protein that shares the functions 
of GMFB and GMFG for development of the nervous 
system and the blood/immune system. As the com- 
plexity of the nervous system and the blood/immune 
system increased in the later stages of vertebrate 
evolution, especially in mammals, it is conceivable 
that the single GMF gene was duplicated and subse- 
quently modified to  give rise to  the GMFB gene and 
the GMFG gene. The observation may provide one 
possible explanation for why the overlapping genes, 
when comparing the stem cell molecular signatures, 
are “negligible” among HSCs, neural stem cells, and 
embryonic stem cells (31). It seems that different 
members of the same gene family are preferentially 
expressed in different systems/tissues to  perform vir- 
tually the same task. Although these members are 
structurally and functionally similar, they have dis- 
tinct characteristics in cDNA microarray analysis. 
Conclusion 
There are two primary features of HSCs: (1) their 
ability to replicate without differentiation, and (2) 
their ability to  differentiate, under specified condi- 
tions, t o  become different types of blood cells. Be- 
cause GMFG (both the mRNA and proteiu forms) is 
present in HSCs and exhibits a differential pattern at 
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Entry TF Score 
-750 CTAAACTCCC 
-740 CTTTTCCAGC CCTGCAATTC AAATATCCCA GATGGGGGTA AATCTAGGAA 
GATA-1 0.363 
MOO083 MZFl 0.330 
---__----_ 
-690 GGCCACCTGG AGGAGGGGAG GAGCAAAATA GTTCGTTTTT AGTACCTATT 
- - - _ _ _ _  
-640 GTGTCTGCCA TGCTGGCAGC TATGTGAAGC TATTTATTTA TTTATTTTTA 
-590 TTTATTTGTA TTTTTATTGC CTGGGATAGA GTGCAATGAT GTGATCTTGG 
-540 CTCACTGCAA CCTCTGCTGC TCGGATTCAA GCAATTCTTG TGCCTCAGAC 
-490 TCCCGAGTAG CTGGGATCAC AGGCGTGCAC CACCATGCCA GGCTAATATT 
-440 TTGTATTTTT AGTAGAGATG GGGTTTTGCC ATGTTGGTCA GGCTGGTCTC 
MOO076 GATA-2 0.921 ____-_- - - -  
GATA-3 0.922 
MOO075 GATA-1 0.906 
<--------- MOO141 Lyf -1  1.000 
<--_-------- MOO073 deltaE 0.926 
<------_---- MOO220 SREBP-1 0.310 
____--- -- 
-____---__ 
-390 CAACTCCTGA CCTCAGGTGA TCCGCCCGCC TCGGCCTCCC ARAGTGCTGG 
-340 CATTACAGGT GTGAGCCACC ATGCCCGGCC GATGTGAAGC TATTTATATC 
-290 CTCACCACAA TCTCAAATCA GAGGGGTGAA GTTACTTAGC TAGGGTCACA 
> CdxA 1.000 




-240 CAGCAAGGAA GCTTTGGAAC CCTGGTCTGA GCGATTTCCT GACAGGTCCT 
-190 GGCAGATGAG GGGAAGGAAG GAGGGGGAGG AGCCCTCTGT GACAGTTGTC 
-140 CCAGAAAGGG CATAAACAGG ATGTGGTGTT GGATGAAACC TTCCTCCTAC 
M00083 MZFl 0.904 
MOO271 AML-la 1.000 
c-Ets-1 0.322 
CdxA 0.910 
M00083 MZFl 0.357 
Spl 0.332 




-90 TGCACAGCCC GCCCCCCTAC AGCCCCGGTC CCCACGCCTA GAAGACAGCG 
<- -_-___- 
<---------- 
-40 GAACTAAGAA AAGAAGAGGC CTGTGGACAG AACAATCATG 
Pbx-1 0.912 
GATA-1 0.902 
- - ---__- 
<----_---- 
Potential Functionflissue SDecific 
erythroid development 
myeloid development, tumor/gmwth suppressor 
in the hematopoietic compartment 
hematopoiesis, erythroid development 
regulates T cell TCR delta gene 
see GATA-1 
early stage of B and T cell development 
regulating angiogenesis in response to VEGF 
mediator of FGF to initiate Hox gene 
master regulator of hematopoiesis 
see GATA-3 
see MZFl 
see AML-1 a 
T cells development, may play role in organ formation 
see CdxA 
see MZFl 
activator, most abundant in thymus and spleen 
cofactor of horneo domain protein in ALL 
see GATA-1 
Fig. 5 Results of GMFG promoter analysis. Only 20 high-score putative TFs were reported. A brief description of T F  
potential function/tissue location is provided. TCR, T cell receptor; VEGF, vascular endothelial growth factor; FGF, 
fibroblast growth factor; ALL, acute lymphoblastic leukemia. 
the protein level during lineage commitment, and also 
based on our functional genomics analysis, we hypoth- 
esize that GMFG plays roles in both features of HSCs. 
That is, GMFG might function to maintain HSCs in 
a self-renewing precursor state, and it might also act 
as a lineage regulator for hematopoiesis. Various pro- 
tein modifications, such as phosphorylation and de- 
phosphorylation, might provide the mechanism(s) by 
which GMFG performs these different functions. 
Materials and Methods 
Cell culture 
We used a liquid culture system that has been pre- 
viously described ( 3 )  for studying erythroid and 
myeloid differentiation of human CD133+ bone mar- 
row stem cells. The procedure was modified slightly 
in that GM-CSF was added along with EPO into 
the erythroid culture system to better study the 
effect of EPO versus G-CSF on the differentiation 
and interconversion between erythroid and myeloid 
lineages in vitro. Briefly, normal human CD133- 
selected bone marrow stem cells were seeded in ery- 
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throid and myeloid culture systems. EPO was used 
for erythroid-specific differentiation and G-CSF was 
used for myeloid-specific differentiation in the pres- 
ence of other cytokines, such as stem cell factor 
(SCF, 50 ng/mL), interleukin-3 (IL-3,lO ng/mL), and 
GM-CSF (10 ng/mL) for both cell culture systems. 
CD133+ stem cells (DO) were grown for 14 d in the 
erythroid culture system with EPO (E14) or in the 
myeloid culture system with G-CSF (G14). El4 cells 
were then recultured for another 14 d in the medium 
containing G-CSF (E14-G14), and G14 cells were 
recultured for 14 d in the medium containing EPO 
(G14-El4). Control cells were grown in the medium 
free of cytokines. Samples from each cell population 
were stained with the Wright-Giemsa stain. 
2-DE 
From each cell culture, the cell pellet (about 1x106 
cells) was dissolved in a cell lysis buffer consisting 
of 8 M urea, 2% (vol/vol) 3-[(3-cholarnidopropyl)- 
dimethylammonio]-propane sulfonate (CHAPS), and 
1% (wt/vol) dithiothreitol (DTT). Approximately 10 
pg of protein was rehydrated overnight in a volume 
of 200 mL of 0.5% (vol/vol) CHAPS, 15 mM DTT, 
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Fig. 6 Molecular evolutionary analysis of GMFG. A. Amino acid sequence alignment of GMFG for selected species. 
For certain species, the protein is indicated as “GMF” instead of “GMFG” because only one GMF gene has been 
identified in these species. B. The result of Sandwich Sequence Alignment used for GMF of carp (Cyprinus carpio). 
The green color indicates the identical residues between carp GMF and human GMFB. The red color indicates identical 
residues between carp GMF and human GMFG. The yellow color indicates residues shared by all three proteins. “+” 
indicates residues that are identical between human GMFB and GMFG, but differ from carp GMF. 
0.5% (vol/vol) IPG buffer, pH 4-7, in a Reswelling 
Tray ( Amersham Bioscience, Uppsala, Sweden) on 
an 11-cm, pH 4-7 IPG strip (Immobiline DryStrip; 
Amersham Bioscience) . Isoelectric focusing of sam- 
ples was performed on a Multiphor I1 Electrophore- 
sis Unit (Amersham Bioscience) for 45,000 Vh us- 
ing the following protocol: 30 min at 150 V, 1 h at 
300 V, 1 h at 1,500 V, and 12 h 20 min at 3,500 
V. Subsequently, IPG strips were equilibrated for 15 
min in equilibration buffer [6 M urea, 30% (wt/vol) 
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glycerol, 2% sodium dodecyl sulfate (SDS) in 0.05 M 
Tris-HC1 buffer, pH 8.81 containing 1% (wt/vol) DTT 
and 0.001% (wt/vol) bromophenol blue. Next, IPG 
strips were equilibrated for 15 min in the equilibra- 
tion buffer containing 250 mM iodoacetamide. 
IPG strips were further processed for second- 
dimension polyacrylamide gel electrophoresis on Ex- 
celGel SDS XL 12-14 according to procedures recom- 
mended by the manufacturer (Amersham Bioscience). 
ExcelGels were silver-stained with Hoefer Processor 
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Plus automatic stainer according to the protocol pro- 
vided by the manufacturer (Amersham Bioscience). 
2-DE1 image analysis 
Scanning of gels was performed on a BioRad GS-800 
Calibrated Imaging Densitometer (BioRad, Veenen- 
daal, Netherlands). Scanned TIFF images were ana- 
lyzed using PDQuest 2D Gel Analysis Software ver- 
sion 7.0 (BioRad). Spots were automatically detected 
and images were checked by eye for undetected or in- 
correctly detected spots. Both spot volume and nor- 
malized spot volume datasets were used for further 
analysis. Average gels were obtained using the Cre- 
ate Average Gel Option of the software. 
Protein identification by MS 
Silver-stained gel spots were destained, and individ- 
ual protein gel spots were subjected to reduction 
and alkylation, followed by an situ digestion with 
sequencing-grade modified trypsin (Promega, Madi- 
son, USA). Peptides from in-gel digests were ana- 
lyzed by capillary LC-MS/MS and matrix-assisted 
laser desorption/ionization (MALDI). A nano high- 
performance liquid chromatography system (LC 
Packings Inc., San Francisco, USA) with a F’usica col- 
umn (0.075~150 mm; packed with PepMapTMC18, 5 
pm, 1OOA; LC Packings, Inc.) was interfaced to a QS- 
TAR mass spectrometer (Applied Biosystems, Foster 
City, USA). Peptides were eluted with a 10-min gradi- 
ent of 5%-40% (vol/vol) followed by another 10-min 
gradient of 40%-95% (vol/vol) acetonitrile contain- 
ing 0.1% formic acid/O.Ol% trifluoroacetic acid at a 
rate of 0.2 pL/min. The QSTAR mass spectrometer 
was set to iteratively acquire a positive time-of-flight 
(TOF) MS scan at 1-s accumulation time between 400 
and 1,700 mlz followed by MS/MS scans at 5-s accu- 
mulation time between 50 and 2,500 m / z  of the three 
most abundant ions from the preceding MS scan. Un- 
processed data files containing MS/MS spectra from 
the QSTAR instrument were submitted to the Mascot 
search engine (Matrix Science Ltd., London, UK) for 
database searching and protein identification using 
the Mascot Daemon application ( 3 2 ) .  The SwissProt- 
Trmbl database and the National Center for Biotech- 
nology Information (NCBI) nonredundant database 
were searched using Homo sapiens as a taxonomic re- 
strictor. 
Geno. Prot. Bioinfo. 
RT-PCR 
RT-PCR was carried out on extracted total RNA as 
described previously ( 3 ) .  Total RNA from cells was 
extracted using TRI Reagent@ (Molecular Research 
Center, Inc., Cincinnati, USA). 2 pg of total RNA 
was reverse transcribed with oligo (dT) and murine 
leukemia virus (MuLV) reverse transcriptase accord- 
ing to the protocol supplied with the GeneAmp RNA 
PCR Core Kit (PE Applied Biosystems) and am- 
plified using Tag polymerase. PCR [28 cycles; melt- 
ing temperature (Tm)= 58”CI was performed with 
the GMFG and glyceraldehyde 3-phosphate dehydro- 
genase (GAPDH) primers. GMFG: forward primer 
= 5’-AAAGAAGAGGCCTGTGGACAG-3’, reverse 
primer = 5’-TGGTTGTTCAGGTCCTAGGG-3’; 
GADPH: forward primer = 5’-GTATCGTGGAAGA 
ACTCATGAC-3’, reverse primer = 5’-TGCCAGT 
GAGCTTCCCGTCAGC-3’. The PCR product size 
for each gene was determined and matched the ex- 
pected size. 
Bioinformatic analysis for GMFG tissue 
distribution 
High-throughput gene expression profiling has be- 
come an important tool for investigating transcrip- 
tional activity of the human GMFG gene in a va- 
riety of biological samples. We gathered all pub- 
lished microarray gene expression datasets in which 
the GMFG gene was expressed. We used Su’s dataset 
(http://expression.gnf.org/) as a key base, in which 
gene expression is profiled from 91 human and mouse 
samples across a diverse array of tissues, organs, 
and cell lines; 101 unique specimens representing 
47 tissue/cell lines are represented. We carried out 
an integrated bioinformatic analysis on GMFG us- 
ing Perou’s dataset on responses of human mam- 
mary epithelial cells to EGF, TGF-beta 1, interferon, 
and growth on Matrigel; Mm’s dataset ( 4 )  on hu- 
man CD34+ hematopoietic stem/progenitor cells; and 
Zhang’s dataset (18) on human CD34+ hematopoietic 
stem/ progeni t or cells. 
Bioinformatic analysis for the promoter 
of the GMFG gene 
We used two computational prediction tools to search 
for TF binding sites: the TFSEARCH program (33) ,  
which employs the Position Weight Matrix method, 
and our GeneKey software (34 ) ,  which uses a novel 
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Shuffled Matrix method. By averaging the two scores 
obtained from TFSEARCH and GeneKey, we defined 
a new score, ranging from 0.0 to 100.0, with a higher 
score indicating a higher probability of a putative TF 
binding site. The 5'-flanking 750-bp promoter region 
of the GMFG gene was analyzed. 
Bioinformatic analysis for GMFG 
molecular evolution 
To better understand the molecular evolution of 
GMFG, we collected the GMFG gene sequences 
from multiple species using our GeneKey software 
( 3 4 )  on data from the NCBI UniGene and ex- 
pressed sequence tag (EST) databases, NCBI Human 
Genome Resources (http://www.ncbi.nlm.nih.gov/ 
genome/guide/human/) , Ensembl Genome Browser 
(http://www.ensembl.org/), and UCSC Human 
Genome Browser (http://genome.ucsc.edu/cgi-bin/ 
hgGateway). GeneKey software was designed to as- 
semble ESTs to cDNA/mRNA sequences and trans- 
late the mRNA to corresponding protein sequences. 
To establish a phylogenetic tree for GMFG, our Ma- 
ligner software (35) was used. Another software pro- 
gram, Sandwich Sequence Alignment, was created 
and used to evaluate the similarities of the third se- 
quence to two, instead of one, family members. 
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